Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc. (PACB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: PacBio designs, develops, and manufactures advanced sequencing solutions, primarily focusing on HiFi long-read sequencing technology for applications in human genomics, infectious disease, oncology, and plant/animal sciences. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $160.0 | $154.0 | +4% |
| Gross Profit | $45.8 | $37.3 | +23% |
| Operating Loss | $(553.9) | $(474.3) | -17% |
| Net Loss | $(546.4) | $(309.9) | -76% |
| Cash, Cash Equivalents, and Investments | $279.5 | $389.9 | -28% |
| Convertible Senior Notes Outstanding | $641.0 | $641.0 | — |
Revenue Composition (2025): Consumables ($82.0M), Instruments ($53.8M), Service and Other ($24.2M).
Backlog: $49.2 million as of December 31, 2025 (down from $58.6 million in 2024).
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 16% increase in consumables revenue and a 36% increase in service revenue, partially offset by an 18% decline in instrument revenue due to fewer Revio system sales (61 units vs. 97 units in 2024).
- Operating Loss Expansion: The operating loss widened significantly due to $383.1 million in restructuring-related costs. This included $359.3 million in accelerated amortization of intangible assets (related to the Omniome acquisition) and $15.0 million in impairment charges for in-process research and development (IPR&D).
- Expense Reduction: Core operating expenses (R&D and SG&A) decreased by $71.1 million due to workforce reductions and strategic shifts, though this was overwhelmed by the non-cash restructuring charges.
- Asset Sale: In a subsequent event (January 30, 2026), the company sold short-read DNA sequencing assets to Illumina Cambridge Limited for approximately $48.1 million in net cash proceeds.
Guidance, Outlook, and Risks
Management Commentary and Strategy
Management is pivoting strategy to prioritize HiFi long-read sequencing and cease development of the high-throughput short-read platform. Key 2026 objectives include accelerating samples onto the Revio platform via new SPRQ-Nx chemistry, expanding the Vega benchtop platform, and advancing clinical strategies. The company does not expect to be profitable in 2026.
Risks and Contingencies
- Liquidity: The company has incurred net losses since inception and expects to continue incurring substantial losses and negative cash flow. It holds $279.5 million in cash and investments, which management believes is sufficient for at least the next 12 months.
- Debt Obligations: Outstanding debt includes $200.0 million in 2029 Notes and $441.0 million in 2030 Notes. The 2029 Notes are subject to negative covenants restricting additional indebtedness.
- Regulatory and Trade: Risks include potential FDA regulation of products currently labeled for research use only (RUO), U.S. government funding cuts (NIH), and trade tariffs impacting supply chains and costs.
- Asset Impairment: Significant non-cash charges were recorded in 2025 due to the strategic decision to abandon the short-read platform, resulting in the write-down of related intangible assets and IPR&D.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $279.5 million cash balance against the projected operating losses and capital requirements for 2026.
- Restructuring Impact: Confirm that the $383.1 million in restructuring charges (primarily accelerated amortization) are non-recurring and will not impact future periods similarly.
- Asset Sale Proceeds: Monitor the receipt of the ~$48.1 million net cash proceeds from the January 2026 asset sale to Illumina and its impact on liquidity.
- Instrument Sales Recovery: Assess the trajectory of Revio and Vega instrument sales, which declined in 2025, to determine if the installed base growth is sufficient to drive consumables revenue.
- Debt Covenants: Review compliance with the negative covenants associated with the 2029 Convertible Senior Notes, particularly regarding the ability to incur new debt.